IMRICOR MEDICAL SYSTEMS INC. — AGM Information 2023

May 11, 2023

==> picture [267 x 84] intentionally omitted <==

Annual General Meeting May 2023

IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR)

WWW.IMRICOR.COM

==> picture [137 x 111] intentionally omitted <==

----- Start of picture text -----

Investors and others
----- End of picture text -----

INVESTOR PRESENTATION | 2

Imricor’s Board of Directors and CFO

==> picture [152 x 183] intentionally omitted <==

==> picture [190 x 182] intentionally omitted <==

==> picture [181 x 183] intentionally omitted <==

==> picture [157 x 176] intentionally omitted <==

Steve Wedan Mark Tibbles Anita Messal Peter McGregor Executive Chair, Deputy Chair, Non-Executive Director Non-Executive Director President, & CEO Non-Executive Director

==> picture [137 x 111] intentionally omitted <==

==> picture [156 x 177] intentionally omitted <==

Jonathon Gut CFO

INVESTOR PRESENTATION | 3

Chair’s Address

==> picture [640 x 540] intentionally omitted <==

Mission

==> picture [137 x 111] intentionally omitted <==

==> picture [790 x 298] intentionally omitted <==

----- Start of picture text -----

Mission
To establish a new standard of care for the $US6bn [1]
cardiac ablation market with real-time iCMR procedures.
Number of iCMR Sites Variety of Procedures Breadth of Geographies
----- End of picture text -----

1. Estimated based on data from United States, Europe, ANZ

INVESTOR PRESENTATION | 5

Key message

Primary Drivers of Value

• Expand indications to complex procedures where iCMR adds the most value

• Ventricular tachycardia (VT) and atrial fibrillation (Afib)

• Expand geographies where realtime iCMR ablations are approved and available • US, ANZ, Middle East, Asia

==> picture [137 x 111] intentionally omitted <==

Additional Drivers of Value

• Grow number of active iCMR sites

• Focus on new iCMR sites owned and controlled by cardiology

• Increase the number of procedures performed at each site

• Increased utilisation of MRI partners to drive the pipeline of iCMR labs

INVESTOR PRESENTATION | 6

2022 Highlights

Sites

• 9 active sites across Europe

• Contracted 3 new sites across Europe

• Expanded company's geographical footprint into Croatia and Italy

• Renewed sales focus on sites owned be Cardiology department

Partnerships

• Two agreements signed with Siemens

• First agreement was an Access-I License Agreement

• Second agreement was a Local Coil Agreement

Products

• Second generation ablation catheter submitted for approval in Europe

• First clinical evaluation of NorthStar-MR 3D Mapping System

• Diagnostic Catheter Technical Review Complete

Trials

• Submitted for approval to commence VT ablation trial

• Trial named Vision-MR Ablation of VT or VISABL-VT

• Received first of two approvals from Leipzig Heart Centre Ethics Committee

==> picture [137 x 111] intentionally omitted <==

New Funding Secured

• Secured a US$1.5 million loan under the North Dakota Commerce Department’s Innovation Technology Loan Fund program

• US$5 million convertible note deal

• A$2.92m placement completed in the September quarter

Other

• US restriction on CHESS depository Interests removed

• Hosted virtual open house investor session

• Jonathon Gut promoted to CFO role

INVESTOR PRESENTATION | 7

NorthStar 3D Mapping System

Creating the central core of every iCMR practice by harnessing the value MRI brings

==> picture [137 x 111] intentionally omitted <==

==> picture [611 x 344] intentionally omitted <==

• System used successfully in human setting with Siemens MRI platform

• Development started in 2023 to interface with GE HealthCare MRI platform

• Working through the SIGNET consortium to interface with Philips MRI platform

Same 3D mapping system experience no matter what kind of MRI system you have

We have shown you can do ablations in the iCMR. NorthStar will deliver the why .

NorthStar is not yet approved for sale

INVESTOR PRESENTATION | 8

Business Update and Outlook

Clinical trials update

Ventricular Tachycardia (VT) – VISABL-VT Trial (EU)

• Testing, and documentation completed for NorthStar to be added to the VISABLVT study

• The Netherlands Central Committee on Research Involving Human Subjects (CCMO) has completed its review of the study protocol with positive results

• The Haga Hospital Ethics Committee reviewed it on 2 May

• Upon approval by the Haga Hospital Ethics Committee, the VISABL-VT trial can begin at that site.

==> picture [137 x 111] intentionally omitted <==

Atrial Flutter(AFL) – VISABL-AFL Trial (US)

• Received an approved Investigational Device Exemption (IDE) from the US Food and Drug Administration (FDA) to commence a global clinical trial to support FDA approval of Imricor’s products in the US

• Following the IDE approval, four sites are confirmed for the VISABL-AFL study, and these sites are currently engaged in the activation process, which includes site contracting and site approval.

• Enrolment to commence in Q3

• Enrollment to commence in Q3

INVESTOR PRESENTATION | 10

Other FY2023 updates

• Twice as many procedures performed in Q1 2023 compared to Q4 2022

==> picture [137 x 111] intentionally omitted <==

• Entered into a Master Services Agreement (MSA) with GE Healthcare in April, where GE Healthcare will pay Imricor to develop to the hardware and software required to make NorthStar operate with the GE HealthCare MRI platform. The project to develop for the GE HealthCare MRI platform has begun

• Conducted our second “Real-time iCMR Ablation Global Summit” in Munich, Germany

• Participated in many medical and scientific congresses, such as annual meetings of:

• The Society for Cardiovascular Magnetic Resonance (SCMR)

• The European Heart Rhythm Association (EHRA) – “ Live in the Box” iCMR ablation presented

• • The German Cardiology Society (DGK)

• (next week) the Heart Rhythm Society (HRS)

INVESTOR PRESENTATION | 11

Path to significant scale	Path to significant scale	Path to significant scale	Path to significant scale
	Today		Growing with new Indications		Expanding Geographies		Addressing Entire Market
iCMR Atrial Flutter		iCMR Ventricular Tachycardia		FDA approval in US		Atrial Fibrillation
Ablations (AFL) in the EU		Ablations (VT) in the EU				Ablations (Afib) worldwide
•	Establishing installed base of iCMR labs	•	Key driver for adoption, with MRI adding significant value	•	Over 1100 sites	•	Same consumable products used for VT
				•	Higher reimbursement
•	Building experience with iCMR environment and workflows	•	Higher ASP and higher reimbursement for VT ablations	•	compared to EU US revenue expected to be approximately 2x EU	• •	Largest volume of procedures Access to full market
					revenue		potential of US$6bn
•	Growing exposure with	•	VISABL-VT clinical trial
	physician publications		expected to begin in 2023,	•	IDE approval received
	and presentations at		expected to catalyse market
	summits and congresses		immediately	•	VISABL-AFL clinical trial
					expected to begin in 2023
•	These sites are set up for
	next step

INVESTOR PRESENTATION | 12

Our focus for the year ahead

==> picture [115 x 356] intentionally omitted <==

2 ~~3~~

1

Commercialisation

VISABL-VT Trial (EU)

VISABL-AFL Trial (US)

• Activating sites

• Increasing procedure volumes across active sites

• Commence trial

  • Commence trial

  • First major step into the significant US market for Imricor

• Expected to catalyse market as value of VT is demonstrated

• Increased utilisation of MRI partners to drive the pipeline of iCMR labs

• Strong focus on labs owned by cardiologist department

==> picture [137 x 111] intentionally omitted <==

==> picture [125 x 356] intentionally omitted <==

INVESTOR PRESENTATION | 13

Contact Information

Investors & Australian Media: Simon Hinsley NWR Communications Email: simon@nwrcommunications.com.au +61 401 809 653

Investors:

Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com

Rest of World Media:

Nick Twohy Vice President, Marketing and Business Development, Imricor Email: nick.twohy@Imricor.com

FOLLOW US

==> picture [33 x 32] intentionally omitted <==

==> picture [28 x 27] intentionally omitted <==

==> picture [31 x 31] intentionally omitted <==